Skip to navigationSkip to main contentSkip to right columnADVERTISEMENTMoby IntelligenceFri, July 31, 2026 at 10:50 PM GMT+2 3 min readBalchem Corporation Q2 2026 Earnings Call Summary - MobyStrategic Performance DriversOur analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.Record quarterly results were driven by broad-based growth across all three segments, fueled by market penetration of specialty nutrients and 'better-for-you' food trends.Human Nutrition and Health (HNH) performance was bolstered by heightened consumer interest in high-protein, high-fiber, and lower-sugar products.Animal Nutrition and Health (ANH) saw significant margin improvement and 15% sales growth, aided by the adoption of encapsulated rumen-protected technologies in the dairy market.The European monogastric business realized higher volumes and margins following the implementation of EU antidumping duties, which restored a level playing field.Specialty Products growth was primarily supported by solid volume and pricing gains within the performance gases business.Management mitigated higher input costs stemming from Middle East conflicts through strategic pricing actions and growth-driven operating leverage.Strategic Outlook and InitiativesManagement expects continued growth in HNH by leveraging an 'always-on' consumer engagement model and targeting specific demographics like GLP-1 users.The company anticipates the publication of a pilot clinical study on choline's impact on Alzheimer's and dementia, which could drive significant future demand.Capital allocation remains focused on a balanced approach, including innovation, capacity expansion, and strategic acquisition opportunities supported by a new $650 million credit facility.The effective tax rate for the remainder of 2026 is projected to trend between 22.5% and 23%.Future growth in the ruminant portfolio is expected to be driven by volume as the company continues to build science-based awareness for its precision-release technologies.Operational and Financial ContextCompleted a refinancing of the revolving credit facility, increasing capacity to $650 million and extending maturity to 2031 with improved pricing grids.Repurchased approximately $29 million of common stock during the quarter, totaling $114 million over the trailing 12 months.The effective tax rate increased to 22.8% from 21.9% in the prior year, primarily due to lower tax benefits from stock-based compensation.Net debt stands at $89 million with a low leverage ratio of 0.3, providing significant flexibility for future M&A.Q&A Session SummaryEvaluation and selection criteria for new nutrient product developmentTerms and Privacy PolicyEU DSA contactPrivacy & Cookie SettingsMore Info